NECFA
SAGE

New England Capital Financial Advisors’s Sage Therapeutics SAGE Stock Holding History

New England Capital Financial Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,153
Closed -$10.5K – 435
2025
Q2 		$10.5K Hold
1,153
– – ﹤0.01% 248
2025
Q1 		$9.17K Hold
1,153
– – ﹤0.01% 242
2024
Q4 		$6.26K Buy
1,153
+260
+29% +$1.59K ﹤0.01% 259
2024
Q3 		$6.45K Buy
893
+243
+37% +$2.23K ﹤0.01% 255
2024
Q2 		$7.06K Buy
650
+516
+385% +$6.61K ﹤0.01% 243
2024
Q1 		$2.51K Hold
134
– – ﹤0.01% 302
2023
Q4 		$2.9K Hold
134
– – ﹤0.01% 307
2023
Q3 		$2.76K Hold
134
– – ﹤0.01% 300
2023
Q2 		$6.3K Hold
134
– – ﹤0.01% 250
2023
Q1 		$5.62K Hold
134
– – ﹤0.01% 285
2022
Q4 		$5.7K Buy
+134
New +$5.12K ﹤0.01% 287

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

New England Capital Financial Advisors's SAGE Position: Q3 2025 in Review

New England Capital Financial Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,153 shares — an estimated $10.5K sold.

New England Capital Financial Advisors first reported a position in SAGE in Q4 2022 and held it in 11 quarters. The position peaked at $10.5K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • New England Capital Financial Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • New England Capital Financial Advisors sold 1,153 Sage Therapeutics shares in Q3 2025, an estimated $10.5K.
  • New England Capital Financial Advisors first reported a position in Sage Therapeutics in Q4 2022 and held it in 11 quarters.
  • New England Capital Financial Advisors's Sage Therapeutics position peaked at $10.5K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on New England Capital Financial Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.